acut
gastroenter
age
character
onset
diarrhea
without
vomit
continu
major
caus
morbid
mortal
children
mostli
resourceconstrain
nation
although
gener
mild
selflimit
diseas
gastroenter
one
common
caus
hospit
associ
substanti
diseas
accord
world
health
organ
diarrhea
defin
passag
three
loos
liquid
stool
per
day
frequent
normal
young
children
suddenli
experi
episod
acut
diarrhea
without
vomit
infecti
gastroenter
far
common
view
global
perspect
gastroenter
children
enorm
public
health
import
worldwid
million
children
still
die
everi
year
reach
fifth
birthday
gastroenter
alon
respons
almost
spite
intens
promot
oral
rehydr
solut
or
commun
level
train
health
care
worker
diarrhea
mortal
remain
unaccept
high
million
children
age
less
year
die
year
gastroenter
almost
live
resourceconstrain
nation
acut
diarrhea
repres
lead
caus
child
mortal
second
age
caus
million
visit
primari
care
provid
year
hospit
admiss
children
age
year
hospit
admiss
children
gener
resourceconstrain
nation
higher
rate
hospit
admiss
compar
rich
us
admiss
rate
nine
per
per
year
children
younger
year
england
year
million
case
gastroenter
occur
commun
million
present
primari
care
europ
rotaviru
infect
account
hospit
gastroenter
onethird
emerg
depart
surprisingli
econom
burden
acut
diarrhea
substanti
manag
cost
also
indirect
cost
absenc
work
parent
caregiv
sick
sever
acut
diarrhea
relat
etiolog
rotaviru
infect
disproportion
implic
sever
case
frequent
requir
worldwid
children
age
less
year
diarrhea
hospit
rotaviru
episod
mild
case
lead
dehydr
requir
doctor
visit
resourceconstrain
nation
one
children
die
europ
rotaviru
infect
account
hospit
gastroenter
onethird
emerg
depart
otherwis
agent
found
predominantli
resourceconstrain
nation
includ
shigella
spp
vibrio
cholera
protozoan
infect
mode
transmiss
mainli
horizont
physic
contact
infect
person
excret
pathogen
frequent
transmit
passag
birth
canal
enteropathogen
escherichia
coli
salmonella
enteroviru
although
rare
passag
germ
also
occur
transplacent
bacteremia
sever
matern
infect
asymptomat
horizont
transmiss
occur
direct
contact
sibl
parent
health
care
worker
case
transmiss
ingest
contamin
water
infant
formula
also
report
viral
infecti
agent
adenoviru
rotaviru
transmit
rel
low
incid
diseas
newborn
result
sever
factor
breastfeed
univers
practic
give
birth
home
rural
villag
improv
social
educ
standard
medic
care
advanc
otherwis
newborn
particularli
suscept
enter
infect
earli
life
due
reduc
local
system
immun
respons
absenc
adequ
intestin
flora
reduc
gastric
acid
newborn
protect
role
gastric
motil
intestin
mucu
still
uncertain
extern
factor
contribut
balanc
intestin
ecosystem
nutrit
type
deliveri
hygien
habit
use
antibiot
mother
infant
supplement
probiot
andor
prebiot
oligosaccharid
mortal
risk
lowbirthweight
infant
less
g
due
acut
diarrhea
time
higher
infant
low
appropri
birth
weight
g
acut
diarrhea
sever
risk
complic
may
lead
lifethreaten
dehydr
electrolyt
disturb
diarrhea
halt
risk
disturb
digest
absorpt
nutrient
nutrit
prevent
essenti
health
profession
ensur
caregiv
educ
follow
main
principl
bacteria
directli
invad
intestin
mucosa
caus
inflammatori
respons
host
other
caus
damag
produc
toxin
classif
alway
well
defin
agent
use
pathogenet
strategi
induc
diseas
europ
common
bacteri
agent
either
salmonella
campylobact
depend
aeromona
hydrophila
plesiomona
shigelloid
previous
also
known
aeromona
shigelloid
belong
famili
vibronace
caus
wateri
diarrhea
pathogen
role
hydrophila
enter
pathogen
caus
gastroenter
difficult
confirm
frequenc
pathogen
isol
hydrophila
symptomat
asymptomat
subject
hydrophila
recogn
increasingli
clinic
signific
enter
pathogen
associ
diarrhea
also
children
younger
year
age
live
rural
commun
link
local
drink
water
campylobact
common
enteropathogen
year
age
particularli
northern
european
jejuni
c
coli
infect
endem
worldwid
hyperendem
resourceconstrain
nation
infant
young
adult
often
jejuni
follow
c
coli
c
lari
common
bacteri
caus
acut
diarrheal
ill
rich
jejuni
invas
properti
lead
epitheli
ulcer
inflammatori
infiltr
lamina
propria
mainli
colon
ileum
jejunum
c
jejuni
isol
elabor
low
level
cytotoxin
similar
shiga
toxin
isol
report
elabor
enterotoxin
similar
cholera
toxin
enterotoxin
product
frequent
observ
isol
resourceconstrain
nation
infect
c
jejuni
associ
wateri
diarrhea
howev
clinic
signific
toxigen
organ
still
symptom
sign
c
enter
distinct
enough
differenti
ill
caus
mani
enter
pathogen
diarrhea
often
associ
blood
difficult
distinguish
invas
form
choleralik
ill
massiv
wateri
diarrhea
may
also
occur
bacteremia
uncommon
less
immunocompet
patient
c
jejuni
newborn
infect
campylobact
spp
rare
case
born
mother
campylobact
diarrhea
time
deliveri
transplacent
passag
campylobact
fetu
respons
abort
prematur
birth
bacteremia
mening
c
jejunicoli
infect
caus
seri
complic
reactiv
arthriti
irrit
bowel
syndrom
syndrom
gb
acut
neurolog
diseas
driven
autoimmun
molecular
mimicri
bodi
stage
cellmedi
humor
immunolog
respons
peripher
nerv
myelin
recent
systemat
review
gb
estim
case
preced
acut
infecti
ill
upper
respiratori
infect
gastrointestin
infect
one
common
enter
due
sever
studi
shown
patient
gb
case
associ
variant
acut
motor
axon
neuropathi
recent
histori
infect
due
c
clostridium
difficil
major
nosocomi
pathogen
caus
spectrum
intestin
diseas
uncompl
antibioticassoci
diarrhea
sever
possibl
fatal
antibioticassoci
last
year
chang
epidemiolog
pattern
c
difficil
infect
character
increas
incid
sever
infect
observ
epidemiolog
studi
recent
conduct
pediatr
popul
demonstr
twofold
increas
incid
c
difficil
infect
last
year
increas
incid
sever
complic
need
colectomi
clinic
present
c
difficileassoci
diseas
rang
asymptomat
carriag
gastrointestin
tract
mild
diarrhea
potenti
fatal
pseudomembran
diarrhea
wateri
usual
nonbloodi
approxim
patient
bloodi
diarrhea
fecal
materi
typic
contain
excess
mucu
pu
blood
may
also
diseas
may
progress
pseudomembran
coliti
possibl
includ
intestin
perfor
toxic
megacolon
neonat
infect
c
difficil
asymptomat
usual
display
fever
diarrhea
irrit
within
hour
product
escherichia
coli
predomin
nonpathogen
facult
anaerob
human
colon
flora
usual
remain
harmlessli
confin
intestin
lumen
e
coli
evolv
abil
caus
broad
spectrum
human
diseas
differ
type
associ
enter
infect
classifi
five
group
accord
virul
properti
briefli
describ
enteroaggreg
e
coli
eaec
serotyp
exhibit
characterist
aggreg
pattern
adher
produc
persist
gastroenter
diarrhea
infant
children
resourceconstrain
enteroinvas
e
coli
serotyp
properti
similar
invas
salmonella
presenc
blood
stool
less
frequent
also
produc
enterotoxin
caus
wateri
diarrhea
resembl
effect
shigella
children
adult
enteropathogen
e
coli
epec
serotyp
past
associ
seriou
outbreak
diarrhea
newborn
nurseri
us
remain
import
caus
acut
infantil
diarrhea
resourceconstrain
nation
diseas
rare
adult
enterotoxigen
e
coli
etec
serotyp
major
caus
travel
diarrhea
diarrhea
children
resourceconstrain
nation
main
hallmark
type
bacteria
express
one
enterotoxin
heatlabil
enterotoxin
heatstabl
enterotoxin
presenc
fimbria
use
attach
host
intestin
cell
enterohemorrhag
e
coli
ehec
serotyp
one
main
caus
foodborn
serotyp
number
rich
countri
primarili
respons
gastroenter
bloodi
diarrhea
sever
abdomin
pain
cramp
resolv
day
adequ
oral
rehydr
sinc
gastroenter
shiga
toxinproduc
e
coli
stec
e
coli
strain
capac
produc
cytotoxin
similar
produc
shigella
spp
identifi
signific
health
problem
develop
infect
stec
ehec
wellknown
serotyp
record
mani
region
includ
north
america
western
europ
central
south
america
middl
far
east
africa
australia
also
eaec
serotyp
produc
shiga
toxin
stec
infect
stec
character
abdomin
cramp
acut
bloodi
diarrhea
howev
seriou
sequela
may
also
result
includ
hemolyt
urem
syndrom
hu
thrombocytopenia
associ
complic
lead
kidney
failur
death
outbreak
sporad
case
bloodi
diarrhea
hu
attribut
strain
stec
serotyp
howev
europ
recent
us
role
stec
strain
eg
nm
caus
hu
bloodi
diarrhea
gastrointestin
ill
increasingli
mani
studi
signific
associ
ill
consumpt
pink
undercook
hamburg
pinkish
ground
beef
undercook
meat
barbecu
food
natur
reservoir
stec
rumin
anim
especi
cattl
transmiss
human
usual
occur
via
contamin
food
water
helicobact
pylori
previous
name
campylobact
pyloridi
infect
children
may
symptom
wide
varieti
symptom
rare
potenti
lifethreaten
complic
gastroduoden
ulcer
bleed
symptom
ulcer
may
includ
pain
discomfort
usual
upper
abdomen
bloat
earli
sens
full
eat
lack
appetit
nausea
vomit
blood
stool
diarrhea
last
year
variou
studi
perform
investig
role
modifi
suscept
gastroenter
studi
report
increas
risk
chronic
diarrhea
compar
healthi
control
subject
among
infect
agematch
gambian
children
nest
casecontrol
design
author
found
increas
risk
sever
cholera
among
h
pyloriinfect
subject
without
vibriocid
similarli
urban
slum
h
pylori
infect
twice
common
among
subject
typhoid
fever
salmonella
typhi
neighborhood
control
subject
anoth
studi
report
increas
diarrhea
episod
among
peruvian
infant
recent
h
pylori
convers
thai
orphanag
associ
found
seroconvers
diarrheal
investig
even
specul
local
inflammatori
factor
induc
infect
may
crosssect
studi
elementari
schoolag
children
germani
infect
seem
associ
reduc
frequenc
diarrheal
epidemiolog
discrep
could
explain
h
pylori
could
argu
increas
decreas
suscept
enter
pathogen
depend
age
acquisit
anatom
site
colon
exampl
h
pylori
decreas
gastric
acid
secret
peopl
therebi
potenti
reduc
effect
gastric
acid
barrier
intestin
pathogen
increas
gastric
acid
secret
prospect
studi
h
pylori
seem
increas
risk
gastroenter
peopl
year
data
recent
klebsiella
enterobact
citrobact
streptococcu
group
isol
fece
sick
newborn
associ
intestin
diseas
insuffici
evid
defin
pathogen
role
agent
proteu
providencia
although
rare
may
respons
intestin
infect
newborn
providencia
speci
occur
normal
fece
isol
epidem
sporad
caus
diarrhea
though
import
causat
diarrheal
diseas
easi
pseudomona
aeruginosa
colon
intestin
newborn
first
day
clinic
infect
may
asymptomat
first
later
develop
grayishblu
stool
color
wateri
diarrhea
profus
vomit
system
salmonella
pass
intestin
mucosa
multipli
within
lamina
propria
may
invad
mesenter
lymphonod
system
spread
organ
occur
give
rise
enter
fact
infant
may
extraintestin
symptom
colon
initi
invas
probabl
occur
distal
ileum
mucos
edema
cryptic
abscess
frequent
colon
diarrhea
due
secret
fluid
electrolyt
small
larg
intestin
incub
period
usual
hour
rare
neonat
infect
salmonella
spp
normal
acquir
birth
canal
mother
asymptomat
shigella
spp
lead
bacteri
caus
diarrhea
worldwid
rel
common
children
caus
invas
gastroenter
symptom
take
long
week
show
often
begin
day
ingest
mild
symptom
selflimit
dysenteria
serotyp
resist
multipl
antibiot
abil
elabor
potent
shiga
toxin
may
lead
extraintestin
complic
includ
hu
case
neonat
infect
staphylococcu
aureu
report
literatur
pathogen
produc
two
enterotoxin
g
caus
atrophi
intestin
villi
diarrhea
poor
growth
first
week
life
vibrio
cholera
caus
wateri
diarrhea
product
cholera
toxin
without
invad
intestin
mucosa
yersinia
enterocolitica
common
enteropathogen
usual
caus
rel
mild
diseas
enterocolitica
cross
intestin
mucosa
replic
peyer
patch
children
infect
present
acut
diarrhea
associ
fever
pharyng
chronic
recurr
diarrhea
abdomin
pain
associ
mesenter
aden
infect
look
like
salmonella
infect
fece
contain
mucu
without
blood
pathogen
within
phagocyt
reach
site
bloodstream
enterocolitica
pathogen
biotyp
express
yst
gene
encod
heatstabl
enterotoxin
may
contribut
pathogenesi
virus
respons
approxim
episod
acut
gastroenter
children
viral
gastroenter
shorter
durat
bacteri
gastroenter
associ
increas
risk
vomit
dehydr
compar
without
viral
infect
sever
dehydr
significantli
higher
children
infect
either
astroviru
rotaviru
group
prolong
hospit
also
like
occur
rotaviru
enter
adenovirus
common
caus
viral
gastroenter
infant
young
children
although
mani
serotyp
adenoviru
found
stool
especi
typic
infect
upper
respiratori
tract
serotyp
caus
gastroenter
difficult
grow
tissu
adenoviru
directli
infect
intestin
enterocyt
caus
villou
hypoplasia
crypt
hypertrophi
viru
caus
massiv
infiltr
lamina
propria
villi
mononuclear
cell
enter
adenoviru
associ
longer
last
diarrhoea
compar
viral
matern
antibodi
certainli
protect
howev
among
prematur
andor
lowbirthweight
infant
infect
spread
rapidli
associ
poor
prognosi
high
cytomegaloviru
herp
viru
cmv
famili
herpesvirida
subfamili
betaherpesvirida
caus
gastrointestin
symptom
diarrhea
coliti
profus
hematochezia
bowel
peopl
infect
nonpolio
enteroviru
ev
famili
picornavirida
genu
enteroviru
diseas
ev
may
caus
human
ev
histor
rare
report
viru
link
respiratori
diseas
last
year
larg
increas
respiratori
diseas
associ
report
document
outbreak
north
america
europ
infect
asymptomat
caus
diarrhea
rash
hand
foot
mouth
diseas
howev
may
respons
sever
complic
includ
mening
enceph
cardiovascular
respiratori
problem
pulmonari
edema
heart
failur
case
fatal
enceph
occur
outbreak
infect
occur
year
age
coxsacki
famili
picornavirida
genu
enteroviru
two
major
pathogen
respons
hand
foot
mouth
diseas
sever
case
associ
pleconaril
viral
agent
activ
enterovirus
demonstr
efficaci
neonat
infect
system
symptom
howev
confirmatori
studi
result
phase
clinic
trial
suggest
vaccin
clinic
accept
safeti
profil
immunogen
outbreak
seriou
socioeconom
burden
western
pacif
region
reason
vaccin
test
seem
accept
safeti
profil
clinic
accept
human
astroviru
famili
astrovirida
genu
mamastroviru
may
also
respons
sporad
infect
epidem
occasion
newborn
human
bocaviru
famili
parvovirida
genu
bocaviru
recent
discov
suggest
involv
larg
spectrum
clinic
manifest
includ
human
coronavirus
hcov
famili
coronavirida
genu
coronaviru
common
caus
upper
respiratori
tract
infect
new
coronaviru
found
caus
agent
sever
acut
respiratori
syndrom
sar
sarshcov
caus
seriou
lower
respiratori
tract
infect
high
mortal
diarrhea
common
condit
one
studi
regist
patient
studi
sarshcov
also
isol
intestin
tissu
viral
rna
detect
stool
sampl
moreov
nonsar
hcov
found
stool
sampl
children
age
howev
hcov
find
coinfect
wellknown
enter
pathogen
noroviru
rotaviru
also
difficult
determin
whether
hcov
respiratori
tract
case
age
primarili
caus
respiratori
gastrointestin
symptom
hcov
may
also
found
occasion
stool
sampl
children
without
gastroenter
find
suggest
known
hcov
may
minor
etiolog
role
age
human
rotaviru
famili
reovirida
genu
rotaviru
past
consid
respons
sever
episod
diarrhea
report
epidem
neonat
intens
care
unit
caus
rotaviru
enteroviru
determin
case
necrot
enterocol
necrot
enterocolitislik
symptom
abdomin
distent
bloodi
diarrhea
septicemia
secondari
enter
bacteria
improv
diagnost
tool
noroviru
famili
calicivirida
genu
noroviru
shown
major
role
epidem
sporad
case
sapovirus
famili
calicivirida
genu
sapoviru
mainli
infect
children
younger
year
ill
milder
caus
antibodi
preval
studi
show
virtual
children
infect
sapovirus
time
year
age
indic
sapoviru
infect
widespread
although
ill
like
sporad
high
rate
asymptomat
torqu
teno
midi
virussmal
anelloviru
ttmdvsav
member
famili
anellovirida
although
human
ttv
infect
ubiquit
sever
infect
genogroup
viru
identifi
date
consist
evid
link
ttv
infect
human
specif
recent
hungarian
studi
viral
shed
molecular
epidemiolog
genet
divers
ttmdvsav
studi
human
bodi
fluid
nasopharyng
aspir
children
acut
respiratori
diseas
serum
stool
urin
sampl
collect
eight
healthi
children
previou
ttmdvsav
infect
studi
shed
ttmdvsav
relat
virus
detect
two
human
bodi
fluid
fece
urin
suggest
exist
transmiss
rout
beyond
origin
presum
bloodborn
latersuggest
respiratori
rout
find
extend
number
possibl
success
transmiss
rout
pathogen
role
candida
neonat
diarrhea
still
difficult
prove
symptom
ascrib
candidaassoci
diarrhea
literatur
includ
prolong
secretori
diarrhea
abdomin
pain
cramp
without
blood
mucu
fever
nausea
dissemin
candida
infect
caus
intestin
symptom
similar
necrot
enterocol
especi
prematur
infant
infant
treat
antibiot
especi
thirdgener
cephalosporin
central
venou
cathet
surgic
infect
frequent
develop
system
form
major
caus
morbid
mortal
neonat
intens
care
incid
candidemia
neonat
intens
care
unit
steadili
increas
estim
incid
lowbirthweight
infant
extrem
lowbirthweight
infectionassoci
mortal
follow
candida
bloodstream
infect
high
low
birth
weight
extrem
low
birth
weight
neurodevelopment
impair
common
among
survivor
extrem
low
birth
weight
invas
fungal
infect
common
extrem
difficult
diagnos
prevent
decreas
risk
factor
contribut
increas
colon
concentr
fungal
organ
like
matern
vertic
transmiss
nosocomi
acquisit
antifung
prophylaxi
waterborn
protozoan
parasit
induc
enter
membraneassoci
function
structur
virul
factor
alter
host
cellular
molecul
signal
pathway
lead
structur
function
lesion
intestin
cryptosporidium
parvum
high
infect
signific
enter
diseas
rare
asymptomat
report
case
infect
first
month
life
passag
matern
antibodi
breastfeed
protect
factor
giardiasi
one
intestin
protozoa
caus
public
health
problem
resourceconstrain
nation
well
resourcerich
countri
mani
infect
person
asymptomat
lead
difficulti
erad
control
parasit
due
number
potenti
carrier
school
children
giardia
lamblia
observ
almost
three
time
asymptomat
children
symptomat
children
first
sign
acut
giardiasi
includ
nausea
loss
appetit
upper
gastrointestin
uneasi
follow
accompani
sudden
onset
explos
wateri
foulsmel
diarrhea
stool
associ
giardia
infect
gener
describ
loos
bulki
frothi
andor
greasi
absenc
blood
mucu
may
help
distinguish
giardiasi
acut
diarrhea
gastrointestin
disturb
may
includ
flatul
bloat
anorexia
cramp
acut
stage
usual
resolv
spontan
day
occasion
acut
infect
persist
lead
malabsorpt
steatorrhea
loss
strength
weight
loss
estim
million
peopl
infect
year
africa
asia
latin
america
resourcerich
countri
preval
rate
giardiasi
howev
resorceconstrain
countri
giardia
lamblia
infect
children
earli
life
thu
preval
rate
children
younger
year
common
children
malnourish
frequent
cryptosporidium
giardia
often
caus
diarrhea
immunocompromis
children
children
resourceconstrain
nation
diarrhea
tend
chronic
although
e
histolytica
gener
caus
bloodi
diarrhea
studi
demonstr
e
histolytica
could
also
respons
wateri
diarrhea
particularli
infant
nondysenter
diarrhea
common
present
amebiasi
children
less
year
age
also
report
among
children
age
year
isospora
belli
opportunist
protozoan
frequent
develop
countri
tropic
subtrop
region
monitor
immunocompromis
immunocompet
patient
gastrointestin
complaint
abdomin
pain
nausea
diarrhea
sever
helminth
also
caus
diarrhea
import
depend
geograph
locat
climat
condit
poor
sanit
unsaf
drink
water
immun
statu
strongyloidiasi
infect
caus
intestin
nematod
strongyloid
stercorali
infect
healthi
individu
usual
asymptomat
howev
caus
wateri
chronic
diarrhea
abdomin
cramp
failur
thrive
cachexia
potenti
fatal
immunocompromis
host
due
capac
caus
overwhelm
hyperinfect
screen
assay
strongyloid
infect
suspect
patient
need
earli
detect
success
trichuri
trichiura
infect
widespread
global
preval
intensityofinfect
peak
school
age
nevertheless
soon
infant
start
explor
environ
thu
come
contact
contamin
soil
risk
infect
accord
level
transmiss
area
pathogen
caus
inflammatori
damag
mucosa
bloodi
diarrhea
iron
defici
anemia
children
gastroenter
requir
laboratori
investig
mani
infant
children
experi
brief
episod
diarrhea
manag
parent
without
seek
profession
advic
even
advic
sought
health
care
profession
often
consid
clinic
assess
requir
laboratori
investig
howev
may
particular
circumst
investig
may
help
diagnosi
frequent
sign
symptom
suffici
make
etiolog
diagnosi
often
nonspecif
local
pathogen
small
intestin
colon
characterist
fece
tabl
clinic
histori
diseas
environment
risk
factor
support
diagnost
evalu
would
also
import
awar
histori
recent
contact
someon
acut
diarrhea
andor
vomit
exposur
known
sourc
enter
infect
possibl
contamin
water
food
recent
travel
sever
wateri
diarrhea
absenc
mucu
pu
blood
suggest
secretori
diarrhea
malabsorpt
noninvas
vibrio
cholera
etec
rotaviru
adenoviru
astroviru
presenc
blood
mucu
indic
invas
germ
salmonella
shigella
campylobact
jejuni
yersinia
presenc
vomit
fever
diarrhea
nonspecif
help
would
also
import
awar
histori
recent
contact
someon
acut
diarrhea
andor
vomit
exposur
known
sourc
enter
infect
possibl
contamin
water
food
recent
foreign
system
symptom
bacteremia
sepsi
spread
organ
lung
bone
mening
may
various
complic
gastrointestin
infect
salmonella
shigella
yersinia
campylobact
c
difficil
detect
stool
specimen
mani
healthi
children
age
year
percent
adult
although
data
support
potenti
endogen
sourc
human
infect
earli
circumstanti
evid
suggest
pathogen
could
transmiss
acquir
extern
therefor
possibl
disord
would
requir
care
consider
case
diarrhea
andor
vomit
shown
tabl
regard
collect
transport
stool
specimen
stool
cultur
bacteri
pathogen
one
stool
specimen
suffici
case
investig
bacteri
pathogen
stool
specimen
deliv
laboratori
soon
possibl
delay
may
compromis
bacteri
pathogen
recoveri
singl
stool
specimen
properli
collect
promptli
submit
identifi
patient
bacteri
pathogen
addit
stool
specimen
need
submit
cultur
result
neg
symptom
persist
caus
found
concern
regard
time
transport
specimen
consult
laboratori
physic
chemic
studi
fece
fecal
ph
less
equal
presenc
reduc
substanc
sign
intoler
carbohydr
mostli
secondari
viral
infect
microscop
examin
stool
presenc
leukocyt
suggest
enteroinvas
infect
although
absenc
leukocyt
exclud
howev
infect
mediat
enterotoxin
etec
vibrio
cholera
virus
white
blood
cell
stool
fecal
cultur
variou
cultur
media
use
isol
bacteria
clinic
histori
physicochem
characterist
stool
laboratori
test
thu
allow
choic
appropri
cultur
medium
presenc
clinic
sign
leukocyt
stool
alway
necessari
perform
cultur
salmonella
shigella
campylobact
stool
cultur
perform
within
hour
sampl
collect
necessari
keep
stool
blood
cultur
examin
evid
bacteremia
research
bacteri
toxin
conduct
enzymelink
immunosorb
assay
elisa
fecal
rotaviru
antigen
examin
elisa
latex
agglutin
test
search
adenoviru
fecal
antigen
perform
use
polymeras
chain
reaction
pcr
molecular
investig
perform
viral
research
especi
stool
noroviru
adenoviru
sapoviru
human
bocaviru
pcr
stool
blood
use
detect
providencia
genusspecif
pcr
method
develop
specif
sensit
evalu
variou
bacteri
recent
pcr
method
appli
investig
preval
virul
gene
specif
five
major
pathogroup
diarrheagen
escherichia
coli
primari
cultur
fece
anim
slaughter
human
consumpt
burkina
faso
reveal
common
occurr
diarrheal
virul
gene
fece
food
anoth
studi
investig
use
pcr
incid
antimicrobi
resist
genet
relationship
epec
children
regard
parasit
infect
studi
trophozoit
oocyst
antigen
detect
stool
elisa
use
serolog
studi
help
rare
system
intestin
infect
enteroinvas
agent
possibl
find
low
blood
level
albumin
high
level
alphalantitrypsin
stool
index
extend
intestin
inflamm
dispers
parent
caregiv
children
inform
possibl
prevent
spread
gastroenter
use
simpl
rule
two
live
oral
attenu
rotaviru
vaccin
licens
pentaval
bovinehuman
recombin
vaccin
monoval
human
rotaviru
vaccin
vaccin
demonstr
good
safeti
efficaci
profil
larg
clinic
trial
resourcerich
countri
latin
immun
rotaviru
recommend
europ
protect
effect
breastfeed
gastroenter
infect
demonstr
sever
antibacteri
substanc
lactoferrin
lysozym
phagocyt
specif
secretori
immunoglobulin
play
protect
ligandspecif
action
inhibit
helicobact
pylori
adher
gastric
mucosa
human
milk
also
antivir
action
lactoferrin
product
digest
lactoferrin
milk
fatti
element
suggest
exclus
breastfeed
contribut
protect
common
infect
infanc
lessen
frequenc
sever
infecti
breastfeed
promot
colon
intestin
ecosystem
predomin
bifidobacteria
lactobacilli
probiot
rather
coliform
enterococci
bacteroid
character
intestin
microflora
infant
fed
author
demonstr
use
formula
supplement
probiot
bifidobacterium
lacti
lactobacillu
gg
decreas
incid
sever
diarrhea
probiot
also
defin
food
supplement
improv
intestin
balanc
benefici
effect
health
abl
balanc
intestin
ecosystem
reduc
durat
sever
diarrheal
infect
especi
cours
rotaviru
infect
probiot
intestin
determin
resist
colon
potenti
pathogen
microb
mechan
competit
inhibit
effect
express
nonspecif
innat
acquir
rhamnosu
gg
lgg
consid
particularli
effect
manag
age
confirm
recent
cochran
review
document
lgg
reduc
durat
diarrhea
mean
stool
frequenc
day
risk
diarrhea
last
accord
recent
cochran
review
saccharomyc
boulardii
reduc
risk
diarrhea
last
day
recent
review
confirm
boulardii
significantli
reduc
durat
diarrhea
hospit
recent
random
control
trial
evalu
efficaci
treatment
lactobacillu
reuteri
dsm
compar
placebo
administr
l
reuteri
reduc
durat
wateri
diarrhea
risk
diarrhea
day
relaps
rate
suggest
probiot
may
decreas
infant
mortal
nosocomi
infect
abil
suppress
colon
transloc
bacteri
pathogen
gastrointestin
tract
sever
metaanalys
evalu
probiot
preterm
infant
suggest
benefici
effect
prevent
necrot
enterocol
death
less
nosocomi
infect
l
reuteri
may
reduc
outcom
immunomodul
bactericid
properti
larg
doubleblind
random
control
trial
rct
use
l
reuteri
perform
test
hypothesi
preterm
infant
studi
suggest
although
l
reuteri
appear
decreas
rate
death
nosocomi
infect
trend
suggest
protect
role
consist
observ
literatur
protect
role
mortal
nosocomi
infect
necrot
enterocol
feed
intoler
durat
hospit
significantli
decreas
prematur
infant
less
use
formula
supplement
probiot
particularli
bifidobacterium
lacti
lactobacillu
gg
seem
decreas
incid
sever
infecti
acut
diarrhea
symbiot
combin
prebiot
probiot
benefici
affect
host
improv
surviv
implant
live
microbi
dietari
supplement
gastrointestin
tract
recent
evalu
two
european
rct
manag
age
studi
promis
present
would
appropri
recommend
use
symbiot
confirmatori
data
dehydr
probabl
main
complic
gastroenter
childhood
classif
patient
hydrat
statu
base
presenc
symptom
sign
presenc
one
sign
symptom
immedi
classifi
patient
sever
case
tabl
summar
manag
moder
sever
patient
requir
close
monitor
patient
extrem
age
life
especi
children
month
requir
meticul
observ
immedi
measur
condit
worsen
accord
current
recommend
oral
rehydr
therapi
ort
consid
treatment
choic
replac
fluid
electrolyt
loss
caus
diarrhea
children
mild
moder
dehydr
intraven
rehydr
treatment
choic
case
failur
ort
reserv
patient
sever
dehydr
elimin
mlkghour
effort
young
scientist
research
led
develop
ort
treatment
dehydr
often
accompani
acut
attack
diarrhea
mani
member
research
team
respons
discoveri
associ
noteworthi
univers
medic
research
center
us
goal
research
devis
effect
therapi
cholerainduc
diarrhea
result
hard
work
develop
new
framework
treatment
would
soon
adopt
throughout
develop
world
key
element
overal
strategi
combat
acut
diarrhea
potenti
fatal
dehydr
accompani
diseas
articl
publish
lancet
confirm
cholera
patient
could
rehydr
oral
simpl
solut
water
salt
sugar
equal
importantli
field
staff
could
easili
train
administ
therapi
state
articl
ort
also
offer
practic
treatment
larg
number
patient
develop
world
access
tradit
intraven
drip
therapi
first
studi
efficaci
ort
compar
intraven
therapi
ivt
conduct
patient
follow
studi
establish
effect
ort
children
acut
diarrhea
trial
also
compar
effect
oral
rehydr
ivt
children
differ
degre
type
dehydr
mild
moder
sever
hypernatrem
dehydr
conclud
use
or
rehydr
children
safe
signific
differ
incid
hyponatremia
hypernatremia
mean
durat
diarrhea
weight
gain
total
fluid
intak
compar
ivt
term
outcom
ort
associ
higher
risk
rehydr
failur
babi
treat
ivt
significantli
longer
stay
hospit
higher
risk
phlebiti
statist
signific
differ
main
reason
failur
or
neither
reduc
frequenc
bowel
movement
fluid
loss
shorten
durat
ill
moreov
unpalat
regular
or
strong
salti
tast
also
decreas
accept
howev
import
aspect
treatment
gastroenter
water
electrolyt
balanc
must
adjust
accord
serum
electrolyt
bodi
water
content
greater
younger
child
water
demand
must
calcul
weight
newborn
infant
tabl
b
differ
or
commerci
avail
tabl
recent
compani
ad
probiot
salin
solut
obtain
quick
balanc
intestin
bacteri
flora
infant
monitor
close
check
statu
nutrit
hydrat
infant
moder
dehydr
suspect
infect
ehec
bloodi
diarrhea
system
symptom
hospit
newborn
high
risk
secondari
complic
ort
milkfeed
often
temporarili
suspend
among
oral
solut
ideal
one
low
osmolar
mosml
sodium
content
mmoll
avoid
high
level
serum
sodium
solut
administ
frequent
small
amount
prevent
vomit
initi
oral
rehydr
mlkg
first
also
consid
give
or
via
nasogastr
tube
patient
unabl
drink
vomit
persist
monitor
regular
clinic
assess
case
failur
oral
rehydr
necessari
establish
appropri
parenter
rehydr
fluid
electrolyt
solut
tabl
pediatr
present
racecadotril
first
author
franc
today
approv
wide
use
seven
european
countri
franc
spain
itali
portug
greec
bulgaria
romania
outsid
antisecretori
drug
peripher
act
enkephalinas
inhibitor
reduc
intestin
water
electrolyt
hypersecret
act
enkephalin
neurotransmitt
gastrointestin
tract
select
stimul
delta
receptor
inhibit
adenyl
cyclas
activ
reduc
intracellular
concentr
camp
thu
reduc
secret
water
electrolyt
intestin
lumen
result
reduct
water
electrolyt
secret
without
chang
intestin
motil
moreov
action
racecadotril
take
place
hypersecret
effect
activ
secretori
baselin
new
data
reconfirm
racecadotril
effect
adjunct
therapi
oral
rehydr
wateri
recent
individu
patient
data
assess
efficaci
use
racecadotril
adjunct
or
compar
or
alon
placebo
raw
data
nine
rct
involv
children
age
month
year
age
avail
analysi
two
trial
compar
effect
racecadotril
treatment
two
rct
kaolinpectin
two
rct
compar
placebo
racecadotril
significantli
reduc
durat
diarrhea
inclus
almost
two
time
patient
recov
time
racecadotril
group
vs
placebo
group
p
interact
treatment
dehydr
rotaviru
infect
type
studi
outpatientinpati
countri
studi
evalu
inpati
ratio
mean
stool
output
racecadotrilplacebo
reduc
p
outpati
studi
number
diarrheal
stool
lower
racecadotril
group
p
respond
analysi
defin
durat
diarrhea
less
day
proport
respond
significantli
higher
racecadotril
group
compar
placebo
group
adjust
dehydr
rotaviru
absolut
risk
differ
confid
interv
associ
number
need
treat
four
secondari
need
care
outpati
significantli
favor
racecadotril
two
studi
also
need
ivt
lower
racecadotril
group
compar
placebo
group
differ
incid
advers
event
group
result
recent
metaanalysi
support
use
racecadotril
adjunct
or
manag
age
children
addit
safeti
racecadotril
children
demonstr
clinic
studi
includ
larg
pre
postaccess
studi
show
racecadotril
favor
adverseev
profil
despit
racecadotril
proven
safeti
efficaci
treat
acut
wateri
diarrhea
costeffect
infant
children
yet
determin
uk
model
highlight
potenti
save
aris
reduct
diarrhea
durat
avoid
reconsult
referr
rate
children
children
present
age
often
high
level
vomit
interfer
oral
rehydr
process
could
limit
success
oral
therapi
ondansetron
wide
use
pediatr
emerg
depart
vomit
age
help
success
deliveri
ort
therebi
reduc
need
treat
ivt
recent
studi
evalu
spectrum
diagnos
ondansetron
use
pediatr
emerg
room
medic
record
patient
month
year
age
given
ondansetron
year
retrospect
review
patient
without
primari
discharg
diagnosi
vomit
gastroenter
defin
nongastroenter
compar
gastroenter
group
nongastroenter
group
includ
subject
older
vs
year
gastroenter
patient
common
primari
diagnos
nongastroenter
discharg
patient
fever
abdomin
paintend
head
injuryconcuss
pharyng
viral
infect
migrain
variant
otiti
media
although
ondansetron
wide
accept
treatment
gastroenter
children
total
use
studi
identifi
broader
spectrum
primari
diagnos
ondansetron
anoth
studi
use
rct
compar
antiemet
placebo
treatment
children
adolesc
age
year
vomit
due
gastroenter
proport
patient
cessat
vomit
hour
intraven
ondansetron
placebo
metoclopramid
group
p
case
author
conclus
oral
ondansetron
increas
proport
patient
ceas
vomit
reduc
number
need
intraven
rehydr
immedi
hospit
today
still
unclear
spite
improv
vomit
ondansetron
worsen
diarrhea
trial
report
statist
signific
increas
frequenc
advers
event
cochran
review
diarrhea
report
side
effect
four
five
ondansetron
accord
antiemet
avail
greatest
evid
efficaci
prevent
nausea
vomit
particularli
treatment
postsurgeri
nausea
vomit
ondansetron
dexamethason
ondansetron
firstlin
treatment
addit
dexamethason
zinc
import
trace
element
enzym
requir
zinc
activ
nearli
transcript
factor
requir
zinc
gene
express
zinc
essenti
epitheli
barrier
integr
tissu
repair
cellmedi
immun
immun
function
zinc
antioxid
antiinflammatori
agent
effect
gastrointestin
structur
diarrhea
associ
signific
zinc
loss
use
zinc
supplement
reduc
durat
sever
diarrhea
children
area
preval
zinc
defici
preval
moder
malnutrit
high
zinc
may
benefit
children
age
month
current
evid
support
use
zinc
supplement
children
month
recommend
zinc
supplement
children
gastroenter
supplement
start
begin
symptom
recommend
dose
durat
therapi
decreas
sever
reduc
number
episod
diarrhea
occur
within
month
follow
intak
physiolog
composit
intestin
microflora
essenti
maintain
appropri
balanc
microbiota
intestin
barrier
probiot
also
defin
food
supplement
improv
intestin
microbi
balanc
host
benefici
effect
health
prevent
outbreak
communityacquir
diarrhea
reduc
colon
infant
pathogen
microorgan
reduc
durat
sever
diarrheal
infect
balanc
intestin
ecosystem
larg
clinic
trial
lactobacillu
reuteri
lgg
saccharomyc
boulardii
shown
best
therapeut
effect
reduc
mean
durat
frequenc
wateri
diarrhea
number
wateri
stool
per
day
improv
stool
consist
particularli
recent
random
doubl
blind
studi
carri
three
italian
pediatr
center
show
l
reuteri
dsm
taken
togeth
standard
or
significantli
reduc
durat
wateri
diarrhea
compar
placebo
day
vs
day
p
day
two
three
treatment
wateri
diarrhea
persist
placebo
l
reuteri
recipi
respect
p
p
moreov
children
receiv
l
reuteri
dsm
significantli
lower
relaps
rate
diarrhea
vs
p
european
societi
gastroenterolog
hepatolog
nutrit
nation
institut
health
clinic
excel
suggest
use
probiot
strain
proven
efficaci
appropri
dose
manag
children
acut
gastroenter
adjunct
rehydr
probiot
symbiot
interest
elicit
healthpromot
properti
host
releas
variou
solubl
lowmolecularweight
molecul
differ
natur
surfac
exogen
protein
peptid
amin
lectin
sirtuin
nucleas
enzym
bacteriocin
fatti
amino
acid
lacton
nitric
oxid
etc
abl
interact
correspond
cell
receptor
repli
quickli
induct
special
set
gene
support
stabil
host
genom
microbiom
modul
epigenom
regul
gene
phenotyp
express
ensur
inform
exchang
numer
bacteri
system
play
import
role
control
mani
physiolog
biochem
genet
function
support
host
health
recent
probiot
l
reuteri
strain
atcc
pta
demonstr
abil
potent
suppress
human
tumor
necrosisfactor
product
lipopolysaccharideactiv
monocyt
primari
monocytederiv
macrophag
children
crohn
diseas
primari
mechan
probioticmedi
immunomodul
transcript
research
confirm
result
shown
l
reuteri
produc
biolog
activ
small
compound
previous
unknown
modul
host
mucos
immun
identif
bacteri
bioactiv
metabolit
correspond
mechan
action
respect
immunomodul
may
lead
improv
antiinflammatori
strategi
chronic
immunomedi
case
age
children
viral
selflimit
need
support
treatment
antibacteri
therapi
serv
adjunct
shorten
clinic
cours
erad
caus
organ
reduc
transmiss
prevent
invas
complic
select
antibacteri
use
acut
bacteri
gastroenter
base
clinic
diagnosi
like
pathogen
prior
definit
laboratori
result
antibacteri
therapi
restrict
specif
bacteri
pathogen
diseas
present
gener
infect
shigella
spp
vibrio
cholera
usual
treat
antibacteri
antibacteri
use
sever
unrespons
infect
salmonella
yersinia
aeromona
campylobact
plesiomona
spp
clostridium
difficil
antibacteri
avoid
ehec
evid
benefit
antibiot
nontyphoid
salmonella
diarrhea
otherwis
healthi
peopl
effect
young
peopl
old
peopl
peopl
sever
extraintestin
diseas
alway
clear
slightli
higher
number
advers
event
note
peopl
receiv
antibiot
treatment
nontyphoid
salmonella
howev
empir
therapi
may
appropri
presenc
sever
ill
bloodi
diarrhea
stool
leucocyt
particularli
patient
risk
factor
illf
debilit
patient
use
system
antibiot
recommend
tabl
benefit
risk
advers
drug
reaction
weigh
prescrib
antibacteri
moreov
major
concern
emerg
antibacterialresist
strain
due
widespread
use
antibacteri
agent
aeromona
spp
produc
induc
resist
penicillin
firstgener
cephalosporin
fact
sever
studi
demonstr
rel
high
resist
rate
cephalothin
trimethoprimsulfamethoxazol
low
rate
resist
found
third
gener
cephalosporin
cefotaxim
ciprofloxacin
chloramphenicol
high
level
resist
mani
antibiot
resist
hydrophila
ciprofloxacin
still
low
may
suggest
ciprofloxacin
quinolon
class
antimicrobi
may
consid
potenti
drug
treatment
bacteri
diarrhea
caus
campylobact
jejuni
antibiot
initi
case
febril
diarrhea
especi
believ
moder
sever
diseas
consid
increas
incid
c
jejuni
resist
great
major
isol
strain
quinolon
administr
azithromycin
empir
acut
diarrhea
indic
could
moreov
erythromycin
treatment
acut
c
jejuni
diarrhea
demonstr
antibacteri
efficaci
reduc
mean
number
day
first
neg
stool
accord
recent
studi
manag
clostridium
difficil
infect
involv
three
basic
principl
support
care
discontinu
precipit
antibiot
initi
effect
antic
difficil
therapi
discontinu
offend
antibiot
may
suffici
resolut
mild
symptom
facilit
reconstitut
normal
enter
c
difficil
infect
children
metronidazol
drug
choic
efficaci
similar
vancomycin
sever
infect
oral
vancomycin
intraven
metronidazol
recommend
linezolid
also
potenti
impact
adult
recurr
less
frequent
fidaxomicin
vaccin
c
difficil
desir
develop
regard
enterobacteriacea
antibioticsuscept
profil
indic
enteropathogen
gener
suscept
meropenem
ceftriaxon
follow
amikacin
ciprofloxacin
almost
enteropathogen
resist
ampicillin
epec
infect
primarili
diseas
infant
younger
year
age
often
contract
travel
hot
countri
form
gastroenter
caus
epec
nurseri
use
antibiot
imipenem
amikacin
gentamicin
fluoroquinolon
seem
use
reduc
morbid
mortal
time
excret
studi
evalu
systemat
manner
valu
antimicrobi
manag
epec
infect
etec
report
import
pathogen
respons
travel
diarrhea
eaec
also
play
import
role
travel
diarrhea
pathogen
geographicbas
approach
travel
diarrhea
treatment
encourag
fluoroquinolon
nonabsorb
rifaximin
drug
choic
travel
highrisk
area
e
coli
predomin
etiolog
agent
latin
america
caribbean
haiti
dominican
republ
africa
leav
azithromycin
travel
south
southeast
asia
well
patient
febril
dysenter
ill
acquir
antibiot
therapi
stec
complic
growth
intestin
tract
lead
diarrhea
patient
would
presum
benefit
antibiot
treatment
elimin
bacteria
howev
system
dissemin
shiga
toxin
type
produc
bacteria
intestin
tract
lead
lifethreaten
complic
includ
neurolog
damag
hu
antibiot
treatment
induc
phage
lytic
cycl
result
increas
shiga
toxin
product
could
lead
seriou
diseas
recent
studi
suggest
normal
flora
profound
impact
shiga
toxin
product
subinhibitori
level
antibiot
target
dna
synthesi
includ
ciprofloxacin
sulfamethoxazoletrimethoprim
increas
shiga
toxin
product
antibiot
target
cell
wall
transcript
translat
ciprofloxacin
sulfamethoxazoletrimethoprim
appropri
treatment
contrast
azithromycin
significantli
reduc
shiga
toxin
level
even
rel
high
level
moreov
erad
rate
report
stec
infect
azithromycin
might
consid
potenti
effect
safe
antibiot
may
use
safe
decolon
stec
longterm
numer
outbreak
well
sporad
case
stec
infect
hu
document
worldwid
numer
report
stec
common
serotyp
associ
hu
especi
children
sever
report
stec
underlin
potenti
caus
sporad
diseas
well
epidem
larg
outbreak
northern
germani
satellit
outbreak
western
franc
caus
eaec
serotyp
express
phageencod
shiga
toxin
clinician
confront
larg
number
mainli
adult
patient
hu
associ
sever
hemolysi
neurolog
medic
center
use
vari
therapeut
regimen
includ
plasmapheresi
glucocorticoid
monoclon
antibodi
eculizumab
current
effect
prophylaxi
treatment
avail
stec
infect
probiot
escherichia
coli
strain
nissl
ecn
seem
effici
antagonist
activ
ehec
strain
serotyp
reduc
growth
outbreak
strain
perfectli
show
genom
plastic
evolut
e
coli
result
horizont
gene
transfer
strain
combin
virul
mechan
two
pathotyp
eaec
ehec
lead
improv
abil
adher
infect
host
cell
furthermor
acquisit
mechan
mediat
increas
antibiot
resist
hamper
patient
treatment
recoveri
strain
conserv
virul
factor
eaec
strain
sever
mobil
genet
element
respons
acquisit
new
function
involv
highfrequ
recombin
mobil
transfer
gene
despit
altern
mechan
evolv
colon
adapt
new
nich
e
coli
strain
maintain
core
genom
sequenc
therefor
share
sever
compon
could
use
target
univers
vaccin
e
coli
consid
increas
antibiot
resist
present
among
e
coli
strain
deriv
uncontrol
use
antibiot
vaccin
promis
approach
control
helicobact
pylori
lead
caus
chronic
gastriti
peptic
ulcer
nonulc
dyspepsia
gastric
adenocarcinoma
mucosaassoci
lymphoid
tissu
lymphoma
erad
pathogen
failur
rate
pediatr
patient
particularli
poor
complianc
antibiot
resist
occurr
side
treatment
regimen
gener
includ
protonpump
inhibitor
lansoprazol
omeprazol
pantoprazol
rabeprazol
dexlansoprazol
esomeprazol
allow
tissu
damag
infect
heal
two
antibiot
reduc
risk
treatment
failur
antibiot
resist
treatment
requir
sever
medic
day
pediatr
patient
gastric
mucos
lesioncaus
h
pylori
infect
revers
process
erad
infect
stop
activ
inflammatori
process
also
restor
mucou
membran
reduc
incid
recurr
gastriti
peptic
ulcer
diseas
lead
prevent
malign
diseas
adjuv
therapi
probiot
studi
recent
recent
random
placebocontrol
doubleblind
studi
children
h
pylori
erad
therapi
receiv
seven
strain
probiot
addit
standard
tripl
regimen
omeprazol
amoxicillin
claritromicin
omeprazol
amoxycillin
furazolidon
compar
patient
tripl
regimen
receiv
placebo
find
report
signific
reduct
treatment
complic
improv
therapeut
outcom
rate
erad
significantli
higher
children
lower
rate
nauseavomit
diarrhea
longterm
success
h
pylori
erad
intervent
prevent
gastric
cancer
depend
recurr
determin
nonadher
demograph
import
specif
antibiot
despit
plesiomona
shigelloid
seem
minor
caus
bacteri
enter
pathogen
implic
gastroenter
outbreak
tropic
region
case
travel
diarrhea
antibacteri
use
case
sever
unrespons
infect
effect
ciprofloxacin
azythromycin
partial
trimethoprimsulfamethoxazol
salmonella
spp
antibiot
initi
case
febril
diarrhea
especi
case
moder
sever
diseas
administr
azithromycin
empir
acut
diarrhea
indic
could
consist
evid
sever
clinic
trial
suggest
antibiot
treatment
ampicillin
amoxicillin
cefixim
azithromycin
cotrimoxazol
shorten
durat
diarrhea
lead
earlier
resolut
clinic
symptom
intramuscular
ampicillin
protect
children
relaps
reduc
carriag
salmonella
infect
significantli
better
placebo
oral
ampicillin
antibiot
usual
avoid
mild
shigella
ill
mild
form
shigella
dysenteri
said
self
limit
shigella
strain
resist
antibiot
use
may
lead
increas
resist
necessari
sever
case
choic
antibiot
use
first
line
shigella
dysenteri
govern
period
updat
local
antibiot
sensit
pattern
shigella
isol
support
prevent
measur
recommend
also
institut
along
antibiot
eg
health
educ
handwash
ciprofloxacin
recommend
drug
choic
patient
bloodi
diarrhea
irrespect
accord
recent
cochran
review
author
find
robust
evid
suggest
antibiot
particular
class
better
belong
differ
class
trial
report
variou
period
time
differ
antibiot
effect
isol
shigella
dysenteri
differ
part
world
ampicillin
cotrimoxazol
nalidix
acid
fluoroquinolon
like
ciprofloxacin
pivmecillinam
ceftriaxon
azithromycin
howev
limit
data
subgroup
studi
suggest
fluoroquinolon
ciprofloxacin
would
effect
betalactam
ampicillin
reduc
diarrhea
among
adult
betalactam
would
effect
fluoroquinolon
reduc
diarrhea
among
children
proven
shigella
dysenteri
emerg
drug
resist
ciprofloxacin
secondlin
drug
pivmecillinam
ceftriaxon
azithromycin
increasingli
report
mani
part
world
multipledrug
india
exampl
sever
shigella
strain
flexneri
dysenteria
boydii
sonnei
isol
children
year
age
resist
ampicillin
cotrimoxazol
ciprofloxacin
nalidix
acid
altern
includ
ceftriaxon
azithromycin
ceftriaxon
inject
drug
azithromycin
limit
therapeut
benefit
organ
easili
develop
resist
note
shigella
spp
util
type
iii
secret
system
transloc
bacteri
protein
invasin
ipaad
ipgd
host
eukaryot
cell
initi
infect
common
virul
shigella
spp
seem
ideal
candid
antigen
subunitbas
broadspectrum
protect
vaccin
prevent
vibrio
cholera
strain
endem
outbreak
within
last
decad
reveal
pattern
antibiot
resist
ampicillin
tetracyclin
trimethoprim
correl
widespread
therapeut
prophylact
administr
treat
sever
case
cholera
antibiot
import
continu
spread
resist
import
therapeut
agent
matter
concern
strain
either
intermedi
resist
resist
ceftriaxon
ciprofloxacin
common
clinic
manifest
yersinia
enterocolitica
infect
selflimit
gastroenter
resolv
spontan
within
enterocolitica
usual
show
vitro
suscept
aminoglycosid
chloramphenicol
doxycyclin
cotrimoxazol
thirdgener
cephalosporin
carabapenem
recent
casecontrol
studi
conduct
among
children
age
less
year
found
enterocolitica
gener
suscept
meropenem
ceftriaxon
ciprofloxacin
follow
ceftazidim
amikacin
almost
enterocolitica
resist
fungal
infect
gastrointestin
tract
common
children
especi
immunocompet
one
neonat
period
candida
infect
frequent
develop
system
fluconazol
prophylaxi
infant
g
mgkg
twice
week
intraven
access
requir
appear
safe
effect
prevent
invas
candida
infect
without
diarrhea
attenu
emerg
fungal
new
echinocandin
anidulafungin
caspofungin
micafungin
recent
introduc
seem
advantag
fluconazol
amphotericin
b
better
meet
need
pediatr
patient
neonat
particular
preterm
infant
invas
candidiasi
andor
diarrhea
candida
spp
infect
micafungin
dosedepend
candidacid
agent
excel
vitro
efficaci
candida
spp
includ
speci
resist
amphotericin
b
approv
treatment
invas
candidiasi
children
includ
preterm
infant
age
less
month
efficaci
safeti
demonstr
comparison
liposom
amphotericin
b
fluconazol
appropri
dose
children
weigh
less
kg
mgkgday
treatment
invas
candidiasi
gastroenter
mgkgday
prophylaxi
prematur
infant
appropri
dose
achiev
appropri
level
brain
parenchyma
mgkgday
infant
weigh
g
mgkgday
weigh
less
g
respect
micafungin
drugdrug
interact
accept
safeti
profil
thu
provid
promis
drug
prophylact
therapeut
manag
invas
candidiasi
micafungin
interact
accept
safeti
data
random
trial
conduct
pediatr
adult
patient
show
subgroup
analysi
caspofungin
micafungin
effect
well
toler
also
strongyloid
stercorali
trichuri
trichiura
caus
diarrhea
strongyloid
stercorali
penetr
host
skin
parasit
human
intestin
lead
burn
pain
tissu
damag
ulcer
edema
obstruct
intestin
tract
diarrhea
well
loss
peristalt
contract
ivermectin
firstchoic
therapi
higher
toler
albendazol
secondchoic
trichuri
trichiura
chiefli
tropic
infect
children
especi
vulner
infect
due
high
exposur
risk
light
infest
worm
frequent
asymptomat
heavi
infest
may
caus
mechan
inflammatori
damag
mucosa
abdomin
pain
profus
chronic
diarrhea
bloodi
diarrhea
mebendazol
seem
firstchoic
therapi
albendazol
secondchoic
therapi
nitazoxanid
show
effect
albendazol
nitazoxanidealbendazol
combin
show
minim
effect
need
develop
new
anthelmint
age
remain
major
problem
children
still
repres
one
lead
caus
ill
cost
death
estim
million
gastroenter
death
occur
year
children
less
year
age
throughout
world
especi
resourceconstrain
countri
rich
countri
transmiss
occur
much
frequent
contamin
food
compar
direct
persontoperson
contact
except
enter
virus
also
transmit
aerosol
format
vomit
case
age
children
viral
selflimit
need
support
treatment
rehydr
oral
intraven
appropri
fluidandelectrolyt
balanc
close
attent
nutrit
remain
central
therapi
may
turn
addit
benefit
limit
hospit
intestin
infect
often
requir
drug
antiemet
antidiarrh
agent
probiot
may
deepli
chang
impact
sever
durat
acut
diarrhea
case
sever
infecti
diarrhea
prolong
cours
sign
inflamm
bloodi
stool
immunosuppress
comorbid
suspect
outbreak
fecal
microbi
analysi
alway
perform
specif
therapi
consid
indic
shorten
clinic
cours
erad
caus
organ
reduc
transmiss
prevent
invas
complic
select
antibacteri
use
acut
bacteri
gastroenter
base
clinic
diagnosi
like
pathogen
definit
laboratori
result
base
epidemiolog
data
collect
organ
materi
etiolog
diagnosi
often
singl
fecal
sampl
studi
etiolog
agent
customari
way
make
etiolog
diagnosi
initi
empir
therapi
may
appropri
case
sever
ill
particularli
infanc
immunocompromis
case
suspect
ehec
serotyp
eaec
serotyp
also
shigella
dysenteria
serotyp
estim
infect
individu
develop
hu
follow
stec
infect
e
coli
commonli
involv
serotyp
antibiot
prescrib
accord
recent
guidelin
moreov
major
concern
emerg
antibacterialresist
strain
due
widespread
use
antibacteri
agent
continu
monitor
antibiot
resist
diarrhearel
bacteri
pathogen
recommend
benefit
risk
advers
drug
reaction
weigh
prescrib
kind
drug
